Trade NPCE anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Neuropace, Inc. (NPCE) is trading at US$14.33, up 1.38% today as of Aug 28, 11:37 EDT. The company has a market capitalisation of US$481.57M. Over the past 52 weeks, NPCE has traded between US$8.88 and US$19.60. On Syfe you can trade NPCE with $0 commission and add it to your watchlist.
| Previous close | US$14.13 |
|---|---|
| Market cap | US$481.57M |
| 52-week range | US$8.88 – US$19.60 |
| Volume | 147.88K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Neuropace, Inc.
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
Year: 2021
--Mizuho Securities Initiates Coverage on NeuroPace With Outperform Rating, $22 Price Target
Jul 23, 11:38 AM · MT Newswires
NeuroPace Says US FDA Approves ECoG Assistant for Improving Epilepsy Outcomes
May 29, 12:43 PM · MT Newswires
NeuroPace Q1 Loss Narrows, Revenue Declines
May 12, 8:32 PM · MT Newswires
NeuroPace Q4 Loss Narrows, Revenue Rises; Shares Gain After Hours
Mar 3, 9:37 PM · MT Newswires
Neuropace, Inc. (NPCE) stock is trading at US$14.33, +1.38% from the previous close of US$14.13.
The market cap for Neuropace, Inc. (NPCE) stock is approximately US$481.57M.
The 52-week high for Neuropace, Inc. (NPCE) stock is US$19.60.
The 52-week low for Neuropace, Inc. (NPCE) stock is US$8.88.
Neuropace, Inc. (NPCE) does not currently pay a dividend.
Stay on top of NPCE
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
